| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8680615 | Alzheimer's & Dementia: Translational Research & Clinical Interventions | 2017 | 11 Pages |
Abstract
Pramlintide use appeared to be safe in the absence of diabetes. The biomarker changes as a result of the pramlintide challenge, which distinguished AD from control subjects and mild cognitive impairment.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Haihao Zhu, Robert A. Stern, Qiushan Tao, Alexandra Bourlas, Maritza D. Essis, Meenakshi Chivukula, James Rosenzweig, Devin Steenkamp, Weiming Xia, Gustavo A. Mercier, Yorghos Tripodis, Martin Farlow, Neil Kowall, Wei Qiao Qiu,